Clinical characteristics and outcome of 124 patients according to p21 gene methylation status
| Characteristic . | Hypomethylated, % (n = 73) . | Hypermethylated, % (n = 51) . | P . |
|---|---|---|---|
| Age | NS | ||
| Younger than 15 y | 56 | 53 | |
| Older than 15 y | 44 | 47 | |
| Sex, M/F | 70/30 | 67/33 | NS |
| WBC | NS | ||
| Below 50 × 109/L | 80 | 75 | |
| Above 50 × 109/L | 20 | 25 | |
| FAB classification | NS | ||
| L1 | 55 | 56 | |
| L2 | 37 | 40 | |
| L3 | 8 | 4 | |
| Blast lineage | NS | ||
| B | 84 | 80 | |
| T | 16 | 20 | |
| NCI risk groups | NS | ||
| Standard | 68 | 63 | |
| Poor | 32 | 37 | |
| PETHEMA risk groups | NS | ||
| Standard | 47 | 40 | |
| Poor | 53 | 60 | |
| Treatment | NS | ||
| PETHEMA 89 | 42 | 40 | |
| PETHEMA 93 | 58 | 60 | |
| BMT | 22 | 27 | NS |
| Best response | NS | ||
| CR | 89 | 90 | |
| Cytogenetic/molecular abnormalities | NS | ||
| BCR-ABL | 14 | 25 | |
| t(1;19) | 4 | 2 | |
| 11q23 | 4 | 2 | |
| c-Myc | 5 | 8 | |
| 7q35-14q11 | 3 | 8 | |
| Hyperdiploidy | 9 | 7 | |
| TEL-AML1 | 9 | 6 | |
| Normal | 42 | 39 | |
| Others | 5 | 3 | |
| NT | 5 | 0 | |
| Relapse | 26 | 61 | < .0001 |
| Death | 30 | 57 | .005 |
| Characteristic . | Hypomethylated, % (n = 73) . | Hypermethylated, % (n = 51) . | P . |
|---|---|---|---|
| Age | NS | ||
| Younger than 15 y | 56 | 53 | |
| Older than 15 y | 44 | 47 | |
| Sex, M/F | 70/30 | 67/33 | NS |
| WBC | NS | ||
| Below 50 × 109/L | 80 | 75 | |
| Above 50 × 109/L | 20 | 25 | |
| FAB classification | NS | ||
| L1 | 55 | 56 | |
| L2 | 37 | 40 | |
| L3 | 8 | 4 | |
| Blast lineage | NS | ||
| B | 84 | 80 | |
| T | 16 | 20 | |
| NCI risk groups | NS | ||
| Standard | 68 | 63 | |
| Poor | 32 | 37 | |
| PETHEMA risk groups | NS | ||
| Standard | 47 | 40 | |
| Poor | 53 | 60 | |
| Treatment | NS | ||
| PETHEMA 89 | 42 | 40 | |
| PETHEMA 93 | 58 | 60 | |
| BMT | 22 | 27 | NS |
| Best response | NS | ||
| CR | 89 | 90 | |
| Cytogenetic/molecular abnormalities | NS | ||
| BCR-ABL | 14 | 25 | |
| t(1;19) | 4 | 2 | |
| 11q23 | 4 | 2 | |
| c-Myc | 5 | 8 | |
| 7q35-14q11 | 3 | 8 | |
| Hyperdiploidy | 9 | 7 | |
| TEL-AML1 | 9 | 6 | |
| Normal | 42 | 39 | |
| Others | 5 | 3 | |
| NT | 5 | 0 | |
| Relapse | 26 | 61 | < .0001 |
| Death | 30 | 57 | .005 |
WBC indicates white blood count; FAB, French-American-British; NCI, National Cancer Institute; PETHEMA, Programa para el estudio y tratamiento de las hemopatias malignas; BMT, bone marrow transplantation; CR, complete remission.